Unmesh
Unmesh Sahasrabuddhe, Palo Alto, CA US
Patent application number | Description | Published |
---|---|---|
20100328323 | VIRTUAL GRAPHICS DEVICE DRIVER - Systems and methods are disclosed to enable switching of graphics processing unit (GPU) resources based on different factors. Embodiments include a virtual graphics driver as an interface between GPU drivers and the applications or graphics framework executing on an electronic device. The virtual graphics driver may switch GPU resources from a first GPU to a second GPU by routing function calls to the first GPU or the second GPU. The switching of GPU resources may be based on power management, system events such as hot-plug events, load management, user requests, any other factor, or any combination thereof. In some embodiments, a virtual frame buffer driver is provided that interfaces with the frame buffer of the GPU and provides a virtual view of the frame buffer to manage additional system application programming interfaces (APIs) during the switch. | 12-30-2010 |
Unmesh Shah, Neshanic Station, NJ US
Patent application number | Description | Published |
---|---|---|
20140057836 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds. | 02-27-2014 |
20150274672 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS - The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included. | 10-01-2015 |
Unmesh Shah, Watchung, NJ US
Patent application number | Description | Published |
---|---|---|
20140296136 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 10-02-2014 |
Unmesh Shah US
Patent application number | Description | Published |
---|---|---|
20150274672 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS - The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included. | 10-01-2015 |